Abstract: A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, for use in combination with a 5-ASA agent, in the treatment of a disease resulting from pathologic inflammation. The combination of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof and 5-ASA agent and use of such combination. A kit-of-parts and a pharmaceutical composition comprising such a combination.

Abstract: A method for the treatment a disease resulting from spondyloarthritis, such as axial spondyloarthritis, psoriatic arthritis and enteropathic arthritis, by administering, to a mammal in need of such treatment, a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.

Abstract: A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, for use in combination with a 5-ASA agent, in the treatment of a disease resulting from pathologic inflammation. The combination of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof and 5-ASA agent and use of such combination. A kit-of-parts and a pharmaceutical composition comprising such a combination.

Abstract: A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutical composition comprising the compound. The compound is useful for the treatment a disease resulting from pathologic inflammation, such as inflammatory bowel disease, psoriasis or rheumatoid arthritis.

Abstract: A method for the treatment a disease resulting from spondyloarthritis, such as axial spondyloarthritis, psoriatic arthritis and enteropathic arthritis, by administering, to a mammal in need of such treatment, a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.

Abstract: The present invention relates to methods of treating mammals affected by, for example, a hyperproliferative disease such as cancer, by administering a tumor-targeted superantigen and a chemotherapeutic agent, whereby the administration of the tumor-targeted superantigen and chemotherapeutic agent reduce the antibody response and enhance the T cell response. The superantigen, wild-type or modified, is fused to a target-seeking moiety, such as an antibody or an antibody active fragment. The combined administration of a superantigen and a chemotherapeutic agent provides enhanced therapeutic effects in a treated animal.

Abstract: The present invention relates to methods of treating mammals affected by, for example, a hyperproliferative disease such as cancer, by administering a tumor-targeted superantigen and a chemotherapeutic agent, whereby the administration of the tumor-targeted superantigen and chemotherapeutic agent reduce the antibody response and enhance the T cell response. The superantigen, wild-type or modified, is fused to a target-seeking moiety, such as an antibody or an antibody active fragment. The combined administration of a superantigen and a chemotherapeutic agent provides enhanced therapeutic effects in a treated animal.

Abstract: The present invention relates to methods of treating mammals affected by, for example, a hyperproliferative disease such as cancer, by administering a tumor-targeted superantigen and a chemotherapeutic agent, whereby the administration of the tumor-targeted superantigen and chemotherapeutic agent reduce the antibody response and enhance the T cell response. The superantigen, wild-type or modified, is fused to a target-seeking moiety, such as an antibody or an antibody active fragment. The combined administration of a superantigen and a chemotherapeutic agent provides enhanced therapeutic effects in a treated animal.

Abstract: A fuel system (1) for a vibratory rammer (2) includes a tank arrangement (3), a diaphragm carburetor (4), a fuel line arrangement (5) and a venting line arrangement (6) for complementary venting of air from the fuel system (1) to the atmosphere. The fuel system (1) also includes a venting valve (7) which is open and closeable to the atmosphere. The tank arrangement (3) includes a primary fuel tank (8) and a secondary fuel tank (11).

Abstract: A vibratory plate includes a sprinkler device (3) for wetting the underside of a base plate (2) of the vibratory plate (1). The vibratory plate also includes a water tank (4) and the sprinkler device (3) has an outlet (8) for passing the water, a valve (11) to control the release of water and a knob (5) for the operation of the valve. A channel (6) guides the released water and is arranged along the front edge of the base plate (2). The channel (6) is arranged with descending inclinations along and from the middle of its length and to both side edges of the base plate (2). The outlet (8) is only arranged for the release of water to the middle of the channel (6).

Abstract: A vibratory plate includes a sprinkler device (3) for wetting the underside of a base plate (2) of the vibratory plate (1). The vibratory plate also includes a water tank (4) and the sprinkler device (3) has an outlet (8) for passing the water, a valve (11) to control the release of water and a knob (5) for the operation of the valve. A channel (6) guides the released water and is arranged along the front edge of the base plate (2). The channel (6) is arranged with descending inclinations along and from the middle of its length and to both side edges of the base plate (2). The outlet (8) is only arranged for the release of water to the middle of the channel (6).

Abstract: A fuel system (1) for a vibratory rammer (2) includes a tank arrangement (3), a diaphragm carburetor (4), a fuel line arrangement (5) and a venting line arrangement (6) for complementary venting of air from the fuel system (1) to the atmosphere. The fuel system (1) also includes a venting valve (7) which is open and closeable to the atmosphere. The tank arrangement (3) includes a primary fuel tank (8) and a secondary fuel tank (11).

Abstract: An operating apparatus (1) controls working revolutions of a vibratory rammer. The operating apparatus (1) includes an operating lever (4) movable between an idle position (2) and a stop position (3) and an engine switch-off function (5) and a fuel shut-off function (6). The engine switch-off function (5) and fuel shut-off function (6) are actuated with the operating lever (4) to be inactive in the idle position (2) or activated in the stop position (3). The engine switch-off function (5) is activated before the fuel shut-off function (6) is activated when the operating lever (4) is moved from the idle position (2) to the stop position (3). The activation ceases in reverse order when the operating lever (4) is moved from the stop position (3) to the idle position (2).

Abstract: The present invention relates to methods of treating mammals affected by, for example, a hyperproliferative disease such as cancer, by administering a tumor-targeted superantigen and a chemotherapeutic agent, whereby the administration of the tumor-targeted superantigen and chemotherapeutic agent reduce the antibody response and enhance the T cell response. The superantigen, wild-type or modified, is fused to a target-seeking moiety, such as an antibody or an antibody active fragment. The combined administration of a superantigen and a chemotherapeutic agent provides enhanced therapeutic effects in a treated animal.

Abstract: The invention is related to compounds of general formula (I) wherein R is methyl, ethyl, n-propyl, iso-propyl, n-butyl or allyl; R′ is methyl, methoxy, fluoro, chloro, bromo, azido, trifluorometlhyl, or OCHxFy, wherein x=0−2, y=1−3 with the. proviso that x+y=3; R″ is hydrogen, fluoro or chloro; with the proviso that R″ is fluoro or chloro only when R′ is fluoro or chloro; R4 is hydrogen or pharmaceutically acceptable inorganic or organic cations; R5 is dimethylamino or nitro; R6 is hydrogen; and when R′ is azido R5 is also ethyl, n-propyl, iso-propyl, methoxy, ethoxy, chloro, bromo, trifluoromethyl, OCHxFy, wherein x=0−2, y=1−3 with the proviso that x+y=3, or R5 and R6 taken together are methylenedioxy; and any tautomer thereof. The invention also relates to pharmaceutical compositions containing a compound of the general formula (I) together with a pharmaceutically acceptable carrier.

Abstract: Compounds of formula (I) and tautomers thereof are effective for the treatment of mammals suffering from diseases resulting from autoimmunity and pathological inflammation.

Abstract: A method for stimulation of transcription factor AP (activator protein)-1 by administering a compound of the formula (I) wherein R is selected from methyl, ethyl, n-propyl, iso-propyl, c-propyl, n-butyl, sec.-butyl, iso-butyl, tert.-butyl, c-butyl, n-pentyl, sec.-pentyl, iso-pentyl, tert.-pentyl, neo-pentyl, c-pentyl, c-hexyl and c-heptyl; RNa and RNb are the same or different and selected from hydrogen, methyl and ethyl; R2, R3, R5 and R6 are independently selected from hydrogen, methyl, methoxy, thiomethyl, hydroxy, fluoro, chloro, bromo, trifluoromethyl, phenyl and benzyl; n is 1, 2 or 3; R′ and R″ are the same or different and selected from methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec.-butyl, and iso-butyl or R′ and R″ together form a saturated heterocyclic ring of 5-7 atoms; and pharmaceutically acceptable salts, hydrates and solvates thereof, to a mammal in need thereof.

Abstract: The invention is related to compounds of general formula (I) 1

Abstract: Compounds of formula (I) 1

Abstract: The invention is directed to a vibrating tamper having a single control lever. The single control lever (4) can be set by an operator to any one of three releasably fixed positions with a snap-action detent device holding the control lever in the position selected by the operator. In the first position, the engine ignition is short-circuited, a fuel valve is closed, a fuel tank venting valve is closed and the throttle is fully closed. In the second position, the engine ignition circuit is enabled, the fuel tank venting valve is open, the fuel valve is open and the throttle control is in a starting/idling position. In the third position, the engine ignition circuit is enabled, the fuel tank venting valve is open, the fuel valve is open and the throttle control is in full-throttle position.